#CKPT hashtag - Bluesky

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates Checkpoint Therapeutics (NASDAQ: CKPT) announced its Q1 2025 financial results and significant corporate updates. The company achieved a major milestone with the FDA approval of UNLOXCYT™ (cosibelimab-ipdl) in December 2024, becoming the first and only PD-L1 blocking antibody approved for treating advanced cutaneous squamous cell carcinoma. In March 2025, Checkpoint entered into a merger agreement with Sun Pharmaceutical Industries, valued at up to $416 million, with the special stockholder meeting scheduled for May 28, 2025.Financial highlights for Q1 2025 include: cash position increased to $33.0 million from $6.6 million in Q4 2024; R&D expenses decreased to $3.8 million from $8.5 million year-over-year; G&A expenses increased to $7.4 million from $2.5 million; and net loss was $11.2 million ($0.19 per share) compared to $10.9 million ($0.33 per share) in Q1 2024.

10 months ago

#CKPT #FBIO Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

www.stocktitan.net/news/CKPT/checkpoint-the...

0 0 0 0

Breakthrough: CKPT Secures FDA Approval and $416M Merger Deal in Transformative Year First PD-L1 treatment approved for advanced skin cancer, plus strategic merger with Sun Pharma. See full analysis of CKPT's milestone achievements and financial outlook.

1 year ago

#CKPT #FBIO Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/CKPT/checkpoint-the...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Mar 10th - #CLSK #QBTS #IQ #WULF #CORZ #BTE #RIG #TRVI #BBAI #CKPT #RDFN #UUUU #UEC #NXE #NOMD #LUNR #LPG #LGMK #HMR #GCI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Halper Sadeh LLC Launches Shareholder Investigations into CKPT, RDFN, BLBX for Potential Legal Violations Halper Sadeh LLC is probing Checkpoint Therapeutics, Redfin, and Blackboxstocks for possible federal securities law breaches and fiduciary duties failures.

Halper Sadeh LLC Launches Shareholder Investigations into CKPT, RDFN, BLBX for Potential Legal Violations #United_States #New_York #Halper_Sadeh #CKPT #RDFN

0 0 0 0

Sun Pharma to Acquire Checkpoint Therapeutics Sun Pharma has announced the acquisition of Checkpoint Therapeutics (CKPT) in a deal valued at up to $355 million, offering $4.10 per share in upfront cash payment plus a contingent value right of up to $0.70 per share. The acquisition centers on UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).The deal represents a 66% premium to Checkpoint's closing price on March 7, 2025. The transaction, expected to close in Q2 2025, requires stockholder and regulatory approvals. Checkpoint reported minimal revenue of $0.04 million and a net loss of $27.3 million for the nine months ending September 2024, with R&D expenses of $19.3 million.Fortress Biotech, Checkpoint's controlling stockholder, will receive royalty payments based on future cosibelimab sales and has agreed to vote in favor of the transaction.

1 year ago

#CKPT #FBIO Sun Pharma to Acquire Checkpoint Therapeutics

www.stocktitan.net/news/CKPT/sun-pharma-to-...

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! With FDA approval of Unloxcyt, bullish vibes are in the air. But watch out for volatility from high short interest and dilution concerns. 📈 Consider a long position at $3.65, targeting $4.00 & $4.20. Stay sharp on market trends! #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! With FDA approval for Unloxcyt, we're seeing potential for a short squeeze. 📈 Mixed signals: RSI neutral, MACD bearish, but positive sentiment could drive gains. Consider a LONG at $3.70, targeting $3.90 & $4.10. High-risk, high-reward! 💡 #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! FDA approval of UNLOXCYT has traders buzzing. Watch for a potential short squeeze with high short interest. Consider going LONG at $3.68, targeting $3.80 & $4.00. Keep an eye on volume for breakout signals. 📈 #FeetrAI #StockMarket #Biotech

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #CKPT ) Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

#StockMarket #News

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! FDA approval for their cancer drug has sparked bullish vibes and a potential short squeeze. While financial health is a concern, today's play: Long at $3.55, target $3.80-$4.00, stop at $3.40. Speculative but promising! 📈 #FeetrAI #Stocks

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! FDA approval sparks buzz and potential short squeeze talk. But tread carefully—technical indicators show caution with bearish momentum. Consider entry at $3.45, targeting $3.70 & $3.90. Stay alert to market volatility and dilution risks! 📈 #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! FDA approval of Cosibelimab sparks interest, but with 16.19% short interest, expect volatility. Oversold RSI at 42.08 & bearish MACD suggest caution. Consider a long position at $3.50, targeting $3.80 & $4.00. Stay sharp, traders! 📈 #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #CKPT! With FDA approval of Unloxcyt, high short interest, and bullish market vibes, Checkpoint Therapeutics is primed for action. Enter at $3.80, target $4.20 & $4.50. Watch for a potential short squeeze! 📈 #FeetrAI #StockMarket #BiotechBoom

0 0 0 0